UCB S.A.: Arthritis, Rheumatoid trials

The registry lists 40 Arthritis, Rheumatoid studies with UCB S.A. as lead sponsor. 1 are open to participants now and 25 have results posted.

Phase 1 5Phase 2 6Phase 3 18Phase 4 5No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic DiseasesRecruitingNCT07712939Phase 1
• A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid ArthritisCompletedNCT04740814Phase 1Results posted
• A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)CompletedNCT04163016Phase 1Results posted
• Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's DiseaseCompletedNCT03357471Phase 3Results posted
• An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044CompletedNCT02319642Phase 3Results posted
• A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid ArthritisCompletedNCT02151851Phase 3Results posted
• The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid ArthritisTerminatedNCT01533714Phase 2Results posted
• A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid ArthritisCompletedNCT01521923Phase 3Results posted
• A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid ArthritisCompletedNCT01519791Phase 3Results posted
• Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to MethotrexateCompletedNCT01500278Phase 4Results posted
• Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid ArthritisCompletedNCT01443364Phase 4Results posted
• Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056TerminatedNCT01296711Phase 2Results posted
• A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)TerminatedNCT01292265Phase 3Results posted
• Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) PatientsCompletedNCT01288287Results posted
• A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis SubjectsCompletedNCT01255761Phase 4Results posted
• Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)CompletedNCT01235598Phase 3Results posted
• Observation of Treatment With Certolizumab Pegol in Daily PracticeCompletedNCT01069419Results posted
• Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal VaccinesCompletedNCT00993668Phase 4Results posted
• Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity StudyCompletedNCT00843778Phase 3Results posted
• Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)CompletedNCT00753454Phase 3Results posted
• Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid ArthritisCompletedNCT00717236Phase 3Results posted
• Rheumatoid Arthritis (RA) Moderate to Low Disease Activity StudyCompletedNCT00674362Phase 3Results posted
• Dosing Flexibility Study in Patients With Rheumatoid ArthritisCompletedNCT00580840Phase 4Results posted
• A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisCompletedNCT00175877Phase 3Results posted
• Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid ArthritisCompletedNCT00160693Phase 3Results posted
• A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisCompletedNCT00160641Phase 3Results posted
• An Open-label Study of CND261 in Seropositive Rheumatoid ArthritisActive, not recruitingNCT07052032Phase 1
• Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)No longer availableNCT03559686
• Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid ArthritisCompletedNCT02430909Phase 2
• Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) InhibitorsCompletedNCT01764321
• Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)TerminatedNCT01577264
• Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab PegolCompletedNCT01526434
• Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) TherapyCompletedNCT01463059Phase 2
• Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) TherapyCompletedNCT01242488Phase 2
• National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)CompletedNCT01095393
• To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using MethotrexateCompletedNCT01009242Phase 1/2
• Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid ArthritisCompletedNCT00548834Phase 3
• Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid ArthritisCompletedNCT00544154Phase 3
• A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisCompletedNCT00160602Phase 3
• A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid ArthritisCompletedNCT00152386Phase 3